Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
1.170
+0.010 (0.86%)
At close: May 12, 2025, 4:00 PM
1.190
+0.020 (1.71%)
After-hours: May 12, 2025, 7:51 PM EDT
Allogene Therapeutics Employees
As of December 31, 2024, Allogene Therapeutics had 229 total employees, including 226 full-time and 3 part-time employees. The number of employees decreased by 4 or -1.72% compared to the previous year.
Employees
229
Change (1Y)
-4
Growth (1Y)
-1.72%
Revenue / Employee
$96
Profits / Employee
-$1,124,847
Market Cap
255.89M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ALLO News
- 6 days ago - Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update - GlobeNewsWire
- 19 days ago - Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire
- 5 weeks ago - Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma - GlobeNewsWire
- 2 months ago - Allogene Therapeutics, Inc. (ALLO) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update - GlobeNewsWire
- 2 months ago - Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update - GlobeNewsWire
- 2 months ago - Allogene: Assessing The Pipeline, Competitive Landscape, And Opportunities - Seeking Alpha
- 2 months ago - Allogene Therapeutics Announces Participation in March Investor Conference - GlobeNewsWire